JPMorgan Chase & Co. decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 3.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,333,964 shares of the medical equipment provider’s stock after selling 2,087,519 shares during the period. JPMorgan Chase & Co. owned 3.81% of Boston Scientific worth $1,504,079,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Acrospire Investment Management LLC raised its position in shares of Boston Scientific by 157.3% in the 2nd quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after acquiring an additional 3,100 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its position in shares of Boston Scientific by 14.3% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock worth $160,000 after acquiring an additional 720 shares in the last quarter. San Francisco Sentry Investment Group CA bought a new position in shares of Boston Scientific in the 2nd quarter worth approximately $191,000. Ironwood Investment Counsel LLC bought a new position in shares of Boston Scientific in the 3rd quarter worth approximately $204,000. Finally, Perkins Capital Management Inc. bought a new position in shares of Boston Scientific in the 3rd quarter worth approximately $204,000. 90.68% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Corporation (BSX) traded down $0.04 during trading on Monday, hitting $28.62. The company had a trading volume of 209,090 shares, compared to its average volume of 6,570,306. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. The stock has a market cap of $39,355.80, a P/E ratio of 23.49, a P/E/G ratio of 2.21 and a beta of 1.00. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $29.93.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the consensus estimate of $0.31. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.27 EPS. research analysts predict that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.

In other Boston Scientific news, EVP Timothy A. Pratt sold 10,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total transaction of $282,200.00. Following the sale, the executive vice president now directly owns 164,681 shares in the company, valued at approximately $4,647,297.82. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy A. Pratt sold 10,104 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $27.46, for a total value of $277,455.84. Following the sale, the executive vice president now owns 185,742 shares in the company, valued at $5,100,475.32. The disclosure for this sale can be found here. Insiders sold a total of 508,864 shares of company stock worth $14,581,669 in the last 90 days. 0.74% of the stock is currently owned by company insiders.

BSX has been the subject of several research reports. Royal Bank Of Canada reissued a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a research report on Friday, September 1st. UBS AG reissued a “buy” rating and issued a $31.00 target price (up previously from $30.00) on shares of Boston Scientific in a research report on Tuesday, August 1st. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research report on Sunday, July 30th. BMO Capital Markets reissued a “buy” rating and issued a $30.00 target price on shares of Boston Scientific in a research report on Friday, October 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $30.77.

TRADEMARK VIOLATION WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/boston-scientific-corporation-bsx-holdings-reduced-by-jpmorgan-chase-co/1729141.html.

Boston Scientific Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.